The proposed changes are relatively modest, yet they represent an important procedural step forward in the implementation of ...

On June 12, 2026, the Centers for Medicare & Medicaid Services (CMS) issued its first proposed rule (Proposed Rule) to codify regulations ...

Permanent rulemaking would replace IPAY 2026–2028 guidance, enabling predictable annual negotiations of up to 20 drugs and defined manufacturer agreement and renegotiation requirements. Formularies ...

On the list of critical health policy topics that policymakers are currently focused on, drug pricing is definitely towards the top. Reducing ...

Medicare's initial drug negotiations yielded savings between 38% and 79% off list prices, sparking a new regulatory push by ...

Presented by Philip Morris International{beacon} Health Care Health Care PRESENTED BY The Big Story CMS proposes codifying, ...

On Monday, the Supreme Court declined to hear appeals from pharmaceutical companies opposing the federal government's ability to negotiate drug prices under Medicare. This decision maintains the lower ...

The Supreme Court this morning declined to hear an appeal from six drug manufacturers that wanted the court to reject the Medicare Drug Price Negotiation Program. The court refused to hear separate ...

CMS floats permanent status for Medicare drug price negotiations, proposing codified rules to secure savings and expand drug selections from 2029 onward.

As the Medicare Drug Price Negotiation Program rolls out, it is exposing long-standing transparency challenges — and opportunities — within the 340B drug discount program. Understanding the ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Administrator for the Centers for Medicare & Medicaid Services Mehmet Oz speaks as U.S.